Patients with relapsed or refractory metastatic solid tumors and the following criteria were considered for enrollment in the trial: NY-ESO-1-positive tumors as demonstrated by immunohistochemistry; HLA-A:02:01 status as demonstrated by high-resolution molecular phenotyping; disease progression with standard-of-care treatment options for their metastatic or locally advanced cancer; adequate clinical performance status; and evidence of measurable disease and fulfilling eligibility criteria. Here, HLA-A is linked to cancer.